-
1 Comment
Xiangxue Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 10.7% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Xiangxue Pharmaceutical Co.,Ltd's total revenue rose by 3.0% to $678M since the same quarter in the previous year.
Its net income has dropped by 81.4% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.6% to $-110M since the same quarter in the previous year.
Based on the above factors, Xiangxue Pharmaceutical Co.,Ltd gets an overall score of 3/5.
| CurrencyCode | CNY |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHE |
| ISIN | CNE100000Y92 |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.46 |
| Dividend Yield | None |
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. Xiangxue Pharmaceutical Co., Ltd. was founded in 1997 and is based in Guangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300147.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
